Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Sanders Bill Would Allow Biosimilar “Pay-For-Data” System

Executive Summary

Biosimilar manufacturers could buy access to existing clinical trial data to use in their applications and avoid conducting some clinical trials, if a bill filed by Sen. Bernard Sanders, I-Vt., is approved.

You may also be interested in...



Biosimilar Application Pathway Likely To Travel Through Courts

The courts likely will get involved in biosimilars even if FDA decides which application pathway a biosimilar would travel, a consultant and former FDA official said.

Biosimilar Application Pathway Likely To Travel Through Courts

The courts likely will get involved in biosimilars even if FDA decides which application pathway a biosimilar would travel, a consultant and former FDA official said.

Biosimilars May Drift, But What Should FDA Do About It?

Another balance FDA likely will have to strike in its emerging biosimilars pathway is letting innovators improve and update manufacturing processes while ensuring similar biologics can remain similar to their reference products.

Related Content

Topics

UsernamePublicRestriction

Register

LL1134025

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel